- FDA Approves Rayaldee (calcifediol) to Treat Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease
21 June 2016
- FDA Accepts Resubmission of New Drug Application for Rayaldee
27 April 2016
- OPKO Receives Complete Response Letter from FDA for Rayaldee New Drug Application
30 March 2016
- FDA Accepts OPKO's New Drug Application for Rayaldee
28 July 2015
- OPKO Announces Submission of Rayaldee NDA
2 June 2015
Drugs Associated with OPKO Health, Inc.
OPKO Health, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.